For Physicians

Our Programs

Roots to Thrive

Ketamine

A 12 week community of practice program, weaving together the medicines of unconditional positive regard, community, and ketamine assisted therapy to find our way back to wholeness

Highlights

  • 12 weekly virtual community of practice meetings
  • Small group supported by two RTT facilitators – a Registered Therapist and Registered Nurse
  • 3 ketamine-assisted therapy sessions with your small group
  • Multiple integration and education sessions
  • Physician referral required by a primary care physician (Family Doctor, Nurse Practitioner or treating Psychiatrist).

Program Cost: $5850 + tax

Roots to Thrive

Psilocybin

An 8 week community of practice program, weaving together the medicines of unconditional positive regard, community, and psilocybin assisted therapy to navigate the complexities of end-of-life distress.

Highlights

  • 8 weekly virtual community of practice meetings
  • Small group supported by two RTT facilitators – a Registered Nurse and Registered Therapist
  • 1 psilocybin-assisted therapy session with your small group
  • Multiple education and integration sessions
  • Physician referral required

Program Cost: $2800 + tax

Program Eligibility

Unique eligibility requirements exist for each of our programs

Roots to Thrive

Ketamine

A 12 week community of practice program, weaving together the medicines of unconditional positive regard, community, and ketamine assisted therapy to find our way back to wholeness

Prerequisites

  • PTSD
  • Depression
  • Substance use disorder
  • Anxiety
  • Disordered eating
  • Disordered sleep

Exclusions

  • Uncontrolled or untreated hypertension (above 150/90)
  • Some hepatic disorders (reviewed case by case)
  • Some kidney disorders (reviewed case by case)
  • Some vascular disorders (reviewed case by case)
  • Presence of active psychotic symptoms
  • Dementia
  • Delirium
  • Inability to tolerate group work
  • Extreme emotional instability
  • Ketamine allergy
  • Pregnancy
  • Medications that reduce the effectiveness of Ketamine:
    • Benzodiazepines
    • Lamotrigine
    • Buprenorphine

Roots to Thrive

Psilocybin

An 8 week community of practice program, weaving together the medicines of unconditional positive regard, community, and psilocybin assisted therapy to navigate the complexities of end-of-life distress.

Prerequisites

  • Terminal diagnosis with limited life expectancy
  • Ambulatory
  • eGFR >20 ml/min
  • AST < 3xULN and bilirubin <50 umol/L
  • Emotional distress that has not successfully responded to other treatments: other treatments failed, patient could not tolerate other treatments, patient is unable to access other treatments, or patient refused other treatments for reasons acceptable to our treatment team. 
  • Patient demonstrates comprehension sufficient for understanding the consent form.

Exclusions

  • Treatment in clinical trial where psilocybin would exclude patient from continuing to recieve treatment.
  • Pregnancy or lactation
  • Poorly controlled insulin-dependent diabetes
  • Currently taking on a daily basis: investigational agents, or  MAO inhibitors. 
    • Patients taking MAO-A inhibitors (especially the irreversible inhibitors) will require a minimum 2-week washout period. The possible concern over serotonin syndrome with these agents is not well documented in the literature, however the long interval before MAO is replenished may warrant a cautious approach based on the patient’s risk factors and warrants oversight from the MRP (Most Responsible Physician)
    • Patients taking MAO-B inhibitors should be assessed on a case by case basis as there is a potential for a heightened response and warrants oversight from the MRP.
  • Active uncontrolled epilepsy. 
  • Cancer has central nervous system involvement. 
  • Paraneoplastic syndrome or a tumor with ectopic hormone production which may place the patient at risk for hypercalcemia, Cushing’s syndrome, or SIADH secretion. 
  • Uncontrolled cardiovascular conditions: uncontrolled hypertension, uncontrolled angina, a clinically significant ECG abnormality (e.g. QT prolongation). 
  • Uncontrolled vascular disease (such as TIA in the last 3-6 months, stroke with loss in mental status, peripheral or pulmonary vascular disease with active claudication). 
  • Severity of depression or anxiety symptoms warranting immediate emergent treatment with antidepressant or daily anxiolytic medication (e.g., due to suicidal ideation) as these patients would require immediate referral to community psychiatry.
  • Current or past history of meeting DSM-5 criteria for (the following diagnoses must have been confirmed by a qualified psychiatrist or psychologist):
    • Schizophrenia; 
    • Psychotic Disorder (unless substance-induced or due to a medical condition); 
    • Borderline Personality Disorder; 
    • Bipolar I Disorder; 
    • Bipolar II Disorder; 
    • Other psychiatric conditions judged to be incompatible with establishment of rapport or safe exposure to psilocybin. 
    • Borderline Personality Disorder, Bipolar I Disorder and Bipolar II Disorder may be considered after a psychiatric consult.
    • Bipolar I would require more in-depth investigation in relation to the history of manic episodes.
  • Meet DSM-5 criteria for Dissociative Disorder 
  • Concurrent use of illicit drugs causing ongoing intoxication 
  • Unstable housing conditions (homelessness)

Conditions requiring special psychiatric consideration:

  • First degree relatives meet DSM-5 criteria for Bipolar Disorder or Schizophrenia.

Intake Process

Step 1

You send in your patient’s referral form.

Step 2

Our intake team meets with the potential participant to ensure they understand the program and have the ability to participate

Step 3

Our mental health team ensures the potential participant fits our inclusion criteria and has the capacity to participate

Step 4

Our medical team ensures it is safe for the participant to have ketamine or psilocybin assisted therapy

Research

Click below to read our most recent research findings.

FAQs

We work collaboratively with the participants’ primary mental health care provider to ensure collaborative safe care. This is a time limited program which compliments other forms of treatment. This is not a substitute for other forms of care and expect participants to maintain a relationship with their care team outside of Roots to Thrive including their referring provider.

  • The program is not yet covered. Some of the physician fees are.
  • WorkSafe has covered some participants.